Aktieanalys

SenzaGen H1 2023: Initial take on H1 2023 results - Redeye

Redeye Publicerad: 24 Aug 2023 08:58

Redeye provides an initial take on SenzaGen’s H1 2023 report. The sales for the first half of the year came in at SEK23.6m, 14% lower than our sales estimate of SEK27.5m. Moreover, EBIT came in at SEK-12.5m, lower than our estimate of SEK-8.5m; however, adjustments for non-cash items were much higher than anticipated. We will provide an update shortly where we expect to make some downward changes to our 2023e estimates; however, we do not expect our fair value range to differ significantly.

Länk till analysen i sin helhet: https://www.redeye.se/research/937811/senzagen-h1-2023-initial-take-on-h1-2023-results?utm_source=finwire&utm_medium=RSS

Nyheter om SenzaGen

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!